計量生物学
Online ISSN : 2185-6494
Print ISSN : 0918-4430
ISSN-L : 0918-4430
癌領域の国際共同治験における留意事項
小川 幸男
著者情報
ジャーナル フリー

2011 年 32 巻 Special_Issue_2 号 p. S133-S137

詳細
抄録

Multi-Regional Clinical Trials (MRCT) have increased for simultaneous new drug development in many therapeutic areas. Primary endpoint in oncology MRCT is usually survival time and two points to be considered should be taken into account in this case. One is different accrual periods among regions and the other is different responses in control treatment among regions. In this paper, we show how they affect actual power to overall result and assurance probabilities by simulation. We also deal with the difference of the approval institutions between Japan and the United States and discuss the issue derived from the difference.

著者関連情報
© 2011 日本計量生物学会
前の記事 次の記事
feedback
Top